The effect of continuous enteral tube feeding on various nutritional parameters in patients with disseminated malignant melanoma during intensive chemotherapy

Smit, J. M.; Mulder, Nanno; Sleijfer, Dt; Bouman, Jan G.; Veeger, W; Koops, Heimen Schraffordt

doi:10.1016/0261-5614(83)90012-2

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have reconfirmed the variable change in weight among patients with NSCLC (Sarna et al, 1994). Weight loss has previously been reported among patients with metastatic melanoma (Smit et al, 1983). Weight maintenance in our patients may reflect less toxic chemotherapy regimens, and control of emesis.…”

Section: Discussionsupporting

confidence: 80%

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study

et al. 2005

View full text Add to dashboard Cite

Chemotherapy exerts a variable effect on nutritional status. It is not known whether loss of body fat or fat-free mass (FFM) during chemotherapy relates to diminished dietary intake, failure to meet elevated energy requirements, or to the presence of an acutephase response. We sought to determine prospective measurements of body mass and composition, resting energy expenditure, energy and protein intake, and C-reactive protein over a course of chemotherapy in 82 patients with advanced cancer. There was a large dropout from the study. Prospective measurements were obtained in 19 patients with non-small-cell lung cancer (NSCLC), 12 with metastatic melanoma and 10 with metastatic breast cancer. There were significant increases in energy intake among patients with metastatic breast cancer, 873 (266 -1480) kJ (mean 95% CI; Po0.01), and metastatic melanoma, 2513 (523 -4503) kJ (Po0.01). Breast cancer patients gained percentage body fat over the course of treatment, 2.1 (0.8 -3.5%). Gain or loss of body fat correlated to mean energy intake throughout chemotherapy in patients with NSCLC (Rs ¼ 0.751; Po0.01) and metastatic breast cancer (Rs ¼ 0.617; Po0.05). The ability to meet or exceed energy requirements led to gains in body fat among patients with metastatic breast cancer and NSCLC, but did not prevent loss of FFM in these groups.

show abstract

Section: Discussionsupporting

confidence: 80%

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Altogether, we identified 21 studies published between 1980 and 2017 and reporting on 31 047 cancer patients as shown in Table . These studies provided acceptably reliable data for all of the 14 cancer entities selected for analysis.…”

Section: Methods and Resultsmentioning

confidence: 99%

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review

Anker

Holcomb

Muscaritoli

et al. 2019

J cachexia sarcopenia muscle

136

118

View full text Add to dashboard Cite

Background Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called ‘orphan diseases’. The cut‐off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population). Methods For this systematic review, we searched at PubMed (from inception to 31 January 2018) to identify clinical studies that assessed the prevalence of cachexia in cancer patients at risk. Studies reporting the prevalence of either cancer cachexia or wasting disease in the top‐10 cancer types and 4 other selected cancer types known to be particularly commonly complicated by cachexia were included in this analysis (i.e. prostate cancer, breast cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, urinary bladder cancer, non‐hodgkin lymphoma, lung cancer, kidney and renal pelvis cancer, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer). We calculated the current burden of cancer cachexia, disease by disease, in the USA and in the EU and compared them to the current guidelines for the definition of orphan disease status. Results We estimate that in 2014 in the USA, a total of 527 100 patients (16.5 subjects per 10 000 people of the total population), and in 2013 in the EU, a total of 800 300 patients (15.8 subjects per 10 000 people of the total population) suffered from cancer cachexia (of any kind). In the 14 separately analysed cancer types, the prevalence of cancer cachexia in the USA ranged between 11 300 (0.4/10 000, gastric cancer) and 92 000 patients (2.9/10 000, lung cancer) and in the EU between 14 300 (0.3/10 000, melanoma of the skin) and 150 100 (3.0/10 000, colorectal cancer). Conclusions The absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds for orphan diseases in the USA and EU. Cancer cachexia in each subgroup separately should be considered an orphan disease.

show abstract

Tube feeding of cancer patients treated with chemotherapy

Vries

Kreumer

Schippers

et al. 1985

Med. Oncol. & Tumor Pharmacother.

View full text Add to dashboard Cite

The effect of continuous enteral tube feeding on various nutritional parameters in patients with disseminated malignant melanoma during intensive chemotherapy

Cited by 3 publications

References 19 publications

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review

Tube feeding of cancer patients treated with chemotherapy

Contact Info

Product

Resources

About